Beatriz Pinheiro Lopes
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Beatriz Pinheiro Lopes has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Daniela Boehm
School of Chemical and Bioprocess Engineering, University College Dublin, D04 V1W8 Dublin, Ireland
2 shared publications - Ana Bela Sarmento-Ribeiro
Laboratório de Oncobiologia e Hematologia, Clinica Universitária de Hematologia, FMUC—Faculty of Medicine, University of Coimbra, Azinhaga de Santa Comba, 3000-548 Coimbra, Portugal
1 shared publication - Ana Cristina Gonçalves
Univ Coimbra, Center for Innovative Biomedicine and Biotechnology (CIBB), 3000-548 Coimbra, Portugal
1 shared publication - Catarina Almeida-Ferreira
Coimbra Institute for Clinical and Biomedical Research (iCBR) Area of Environment Genetics and Oncobiology (CIMAGO), Institute of Biophysics, Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
1 shared publication Fiona O'NEill
TheraDep Ltd., QUESTUM Innovation Centre, Clonmel, Ireland; Plasma Research Group, School of Biosystems and Food Engineering, University College Dublin, Dublin 4, Ireland
1 shared publication- Francisco Caramelo
Laboratory of Biostatistics and Medical Informatics (LBIM), Faculty of Medicine, University of Coimbra, 3000-548 Coimbra, Portugal
1 shared publication
Latest Publications
- Open Access
- 1 January 2024
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 14 (2) , 55-77
Feasibility and Efficacy of Cold Plasma for Direct Deposition of Topotecan
Cold plasma therapy is emerging as an innovative modality, with the potential to exhibit synergistic effects when combined with chemotherapeutic agents. A new plasma-assisted local delivery of oncology drugs was developed to mediate the drug delivery and possibly enhance the drug uptake and chemotherapeutical action. Topotecan (TPT) was selected as the candidate drug because despite the potent antitumor activity, the systemic administration is limited. The influence of the plasma deposition process on the characteristics of TPT, was investigated to determine potential structure and activity changes. Fluorescence analysis showed that the emission spectrum of TPT is altered by modifications to the A-ring, influenced by solvent polarity, pH, and moisture content, while deposition parameters and surface characteristics also played important roles, but no structural changes to the A-ring were indicated with plasma exposure. A TPT solution was sprayed into a non-thermal plasma and deposited onto polystyrene microplates. Results showed that the TPT elution from the microplates into cell culture medium was almost complete and instantaneous. Initial findings with U251-mg glioblastoma cell line model suggest that plasma deposition enhances drug stability without compromising biological activity compared to a wet deposition of TPT. This result was confirmed using High Performance Liquid Chromatography. These results reveal a new mode of delivery for effective topotecan therapeutic use and can open the doors to new combinations for local drug application.
- 1 January 2024
- Published by Begell House Inc. Publishers in Plasma Medicine
- Vol. 14 (2) , 55-77
Open AccessFeasibility and Efficacy of Cold Plasma for Direct Deposition of Topotecan
Cold plasma therapy is emerging as an innovative modality, with the potential to exhibit synergistic effects when combined with chemotherapeutic agents. A new plasma-assisted local delivery of oncology drugs was developed to mediate the drug delivery and possibly enhance the drug uptake and chemotherapeutical action. Topotecan (TPT) was selected as the candidate drug because despite the potent antitumor activity, the systemic administration is limited. The influence of the plasma deposition process on the characteristics of TPT, was investigated to determine potential structure and activity changes. Fluorescence analysis showed that the emission spectrum of TPT is altered by modifications to the A-ring, influenced by solvent polarity, pH, and moisture content, while deposition parameters and surface characteristics also played important roles, but no structural changes to the A-ring were indicated with plasma exposure. A TPT solution was sprayed into a non-thermal plasma and deposited onto polystyrene microplates. Results showed that the TPT elution from the microplates into cell culture medium was almost complete and instantaneous. Initial findings with U251-mg glioblastoma cell line model suggest that plasma deposition enhances drug stability without compromising biological activity compared to a wet deposition of TPT. This result was confirmed using High Performance Liquid Chromatography. These results reveal a new mode of delivery for effective topotecan therapeutic use and can open the doors to new combinations for local drug application.
- Open Access
Combined Effect of Plasma-Activated Water and Topotecan in Glioblastoma Cells
The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding GBM treatment, the final outcome is still very poor, making it necessary to develop new therapeutic approaches. Cold atmospheric plasma (CAP) as well as plasma-activated liquids (PAL) are being studied as new possible approaches against cancer. The anticancer activity of PAL such as “plasma-activated water” (PAW) is dependent on the reactive chemical compounds present in the solution. Possible combinatory effects with conventional therapies, such as chemotherapeutics, may expand the potential of PAL for cancer treatment. We aim to explore the therapeutic properties of a combination of PAW and topotecan (TPT), an antineoplastic agent with major cytotoxic effects during the S phase of the cell cycle, on a GBM cancer cell line (U-251mg). Combined treatments with PAW and TPT showed a reduction in the metabolic activity and cell mass, an increase in apoptotic cell death and a reduction in the long-term survival. Single applications of PAW+TPT treatments showed a cytotoxic effect in the short term and an antiproliferative effect in the long term, warranting future exploration of combining PAW with chemotherapeutic agents as new therapeutic approaches.
Open AccessCombined Effect of Plasma-Activated Water and Topotecan in Glioblastoma Cells
The increase in cancer diagnoses and cancer deaths, severe side effects of existing treatments and resistance to traditional treatments have generated a need for new anticancer treatments. Glioblastoma multiforme (GBM) is the most common, malignant and aggressive brain cancer. Despite many innovations regarding GBM treatment, the final outcome is still very poor, making it necessary to develop new therapeutic approaches. Cold atmospheric plasma (CAP) as well as plasma-activated liquids (PAL) are being studied as new possible approaches against cancer. The anticancer activity of PAL such as “plasma-activated water” (PAW) is dependent on the reactive chemical compounds present in the solution. Possible combinatory effects with conventional therapies, such as chemotherapeutics, may expand the potential of PAL for cancer treatment. We aim to explore the therapeutic properties of a combination of PAW and topotecan (TPT), an antineoplastic agent with major cytotoxic effects during the S phase of the cell cycle, on a GBM cancer cell line (U-251mg). Combined treatments with PAW and TPT showed a reduction in the metabolic activity and cell mass, an increase in apoptotic cell death and a reduction in the long-term survival. Single applications of PAW+TPT treatments showed a cytotoxic effect in the short term and an antiproliferative effect in the long term, warranting future exploration of combining PAW with chemotherapeutic agents as new therapeutic approaches.
- 1 August 2021
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 171, 302-313
Plasma activated media and direct exposition can selectively ablate retinoblastoma cells
- 1 August 2021
- Published by Elsevier in Free Radical Biology and Medicine
- Vol. 171, 302-313
Plasma activated media and direct exposition can selectively ablate retinoblastoma cells